Back to search

Poland· PL-100112718

Caelyx pegylated liposomal

A doxorubicin product containing doxorubicinum, registered in Poland by Baxter Holding B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC L01DB01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCaelyx pegylated liposomalATCL01DB01REGISTER NO.PL-100112718PACKS LISTED10CHECKEDSeptember 27, 2026

Where it is registered

Doxorubicin is registered in 17 of 19 countries.

Countries holding a registration under ATC L01DB01 (doxorubicin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Doxorubicin · ATC L01DB01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of doxorubicin costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Doxorubicin · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$12.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Doxorubicinum
Manufacturer
Baxter Holding B.V.
Country
Poland (PL)
ATC code
L01DB01
ATC class
Doxorubicin
Defined daily dose
5 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 10

  • gtin
    05909990983018
  • gtin
    05413765811814
  • gtin
    05413765812101
  • gtin
    05413765812095
  • gtin
    00085412949345
  • gtin
    00085412949765
  • gtin
    00085412948409
  • gtin
    05909990983025
  • gtin
    05909990983032
  • gtin
    05909990983049

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

775 interactions on record for doxorubicin.

Graded by severity as the source publishes them — 98 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Doxorubicin · interactions on record

775 records

  • 98 severe
  • 383 moderate
  • 29 minor
  • 265 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Doxorubicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All doxorubicin products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Adriblastin, Doxorubicin Accord
  • Belgium · Adriblastina Ready To Use, Doxorubicin Accord Healthcare
  • Bulgaria · Доксорубицин Акорд
  • Cyprus · Adriblastina
  • Czechia · Doxorubicin Ebewe, Doxorubicin Medac
  • Germany · Adriacept Blasen-Instillations-Set, Adrimedac
  • Denmark · Adriamycin, Doxorubicin Accord
  • Estonia · Doxorubicin Accord
  • Spain · Doxorubicina Accord, Doxorubicina Aurovitas
  • Finland · Doxorubicin Accord, Doxorubicin Medac
  • France · Adriblastine, Doxorubicin Teva
  • United Kingdom (Northern Ireland) · Doxorubicin Accord Healthcare, Doxorubicin Hydrochloride Medac
  • Greece · Adriblastina, Doxiprol
  • Croatia · Doxorubicin Pliva, Sindroxocin
  • Hungary · Doxorubicin Accord, Doxorubicin Sandoz
  • Ireland · Doxorubicin Accord Healthcare Ireland, Doxorubicin Rivopharm
  • Iceland · Caelyx Pegylated Liposomal, Doxorubicin Medac
  • Italy · Adriblastina, Doxorubicin Teva
  • Liechtenstein · Caelyx Pegylated Liposomal, Myocet Liposomal
  • Lithuania · Doxorubicin Accord, Doxorubicin Ebewe
  • Luxembourg · Adriblastina Ready To Use, Doxorubicine Teva
  • Latvia · Doxorubicin Accord
  • Malta · Doxorubicin Accord Healthcare
  • Netherlands · Doxorubicin Hydrochloride Eugia, Doxorubicine Accord
  • Norway · Adriamycin, Caelyx Pegylated Liposomal
  • Portugal · Doxorrubicina Accord, Doxorrubicina Aurovitas
  • Romania · Doxlox, Doxorubicină Accord
  • Sweden · Doxorubicin Accord, Doxorubicin Ebewe
  • Slovenia · Doksorubicin Accord, Doksorubicin Sandoz
  • Slovakia · Doxorubicin Medac, Doxorubicin Sandoz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dda1744e-6aaa-4744-8aca-4fffabb502cd
GET /v1/drugs/dda1744e-6aaa-4744-8aca-4fffabb502cd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "2 mg/ml",
  "packaging": "05909990983018 ¦ Rpz ¦ EU/1/96/011/001 ¦ 20316\n1 fiol. 10 ml\n¦ UR/Z/4c/097/22 - 05413765811814 ¦ UR/Z/4c/086/22 - 05413765812101 ¦ UR/Z/4c/145/23 - 05413765812095 ¦ UR/Z/4c/064/24 - 05413765812095 ¦ UR/Z/4c/067/23 - 05413765811814 ¦ UR/Z/4c/146/23 - 05413765812095 ¦ UR/Z/4c/024/23 - 05413765811814 ¦ UR/Z/4c/069/24 - 00085412949345, 00085412949765 ¦ UR/Z/4c/140/24 - 00085412949345 ¦ UR/Z/4c/145/26 - 00085412948409\n05909990983025 ¦ Rpz ¦ EU/1/96/011/002 ¦ 20317\n10 fiol. 10 ml\n05909990983032 ¦ Rpz ¦ EU/1/96/011/003 ¦ 23842\n1 fiol. 25 ml\n05909990983049 ¦ Rpz ¦ EU/1/96/011/004 ¦ 23843\n10 fiol. 25 ml",
  "substance": "Doxorubicini hydrochloridum 2 mg",
  "common_name": "Doxorubicinum",
  "pl_product_id": "100112718",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about doxorubicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.